Newamsterdam Pharma N V (NAMS) Gross Profit Margin starting from the second quarter 2026 to second quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Newamsterdam Pharma Company N v   (NASDAQ: NAMS)


Newamsterdam Pharma N V 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NAMS Gross Profit Margin (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3 		(Jun 30 2025)
Q2
Y / Y Revenue Change -80.67 %
Seq. Revenue Change 21.74 %
Revenue In Millions $3.70
Gross Profit Margin 24.86 %
Gross Profit Margin Total Ranking #
Gross Profit In Millions $0.92
Y / Y Gross Profit Change -93.81 %
Seq. Gross Profit Change -


Commenting Second Quarter 2026 Gross Profit Margin
Newamsterdam Pharma Company N v achieved Gross Profit of $1 millions compare to Gross Loss of $0.00 millions recorded in the previous quarter. Revenue increased by 21.74 % Company accomplished below the average Gross Profit Margin with 24.86 %.


Observing second quarter 2026 results within Major Pharmaceutical Preparations industry Newamsterdam Pharma Company N v has achieved highest Gross Profit Margin. While overall Gross Profit Margin ranking remained unchanged compared to the previous quarter at no. .
Learn about Gross Margin
NAMS's Gross Profit Margin second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall # 0

Gross Profit Margin Statistics
High Average Low
84.16 % 62.57 % 24.86 %
(Sep 30 2024)   (Jun 30 2026)


NAMS Gross Income Trends • More of NAMS's Profitabilty Ratios • NAMS Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
NAMS's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
NAMS's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for NAMS's Competitors
Gross Profit Margin Profit Margin for Newamsterdam Pharma N V 's Suppliers
Gross Profit Margin Profit Margin for NAMS's Customers

You may also want to know
NAMS's Annual Growth Rates NAMS's Profitability Ratios NAMS's Asset Turnover Ratio NAMS's Dividend Growth
NAMS's Roe NAMS's Valuation Ratios NAMS's Financial Strength Ratios NAMS's Gross Profit Growth
NAMS's Roa NAMS's Inventory Turnover Ratio NAMS's Growth Rates NAMS's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginJun 30 2026 MRQ Gross ProfitJun 30 2026 MRQ Revenue
Johnson and Johnson  68.19 %$ 17,259.000  Millions$ 25,310.000  Millions
Evolus Inc   68.00 %$ 57.180  Millions$ 84.084  Millions
Eton Pharmaceuticals Inc   67.61 %$ 25.413  Millions$ 37.589  Millions
Fortress Biotech Inc   67.18 %$ 12.575  Millions$ 18.718  Millions
Citius Pharmaceuticals Inc   67.07 %$ 1.002  Millions$ 1.494  Millions
Citius Oncology Inc  67.07 %$ 1.002  Millions$ 1.494  Millions
Journey Medical Corp  66.81 %$ 12.367  Millions$ 18.510  Millions
IMPACT BIOMEDICAL INC.  66.67 %$ 0.002  Millions$ 0.003  Millions
Ainos Inc   65.13 %$ 0.000  Millions$ 0.000  Millions
Aytu Biopharma Inc  64.63 %$ 10.409  Millions$ 16.106  Millions
Zomedica Corp   63.51 %$ 6.041  Millions$ 9.512  Millions
Longeveron Inc   63.41 %$ 0.182  Millions$ 0.287  Millions
Abeona Therapeutics Inc   63.30 %$ 7.203  Millions$ 11.380  Millions
Ani Pharmaceuticals Inc  62.35 %$ 165.886  Millions$ 266.044  Millions
Polomar Health Services, Inc.  61.22 %$ 0.936  Millions$ 1.529  Millions
Clene Inc   60.00 %$ 0.054  Millions$ 0.090  Millions
Emergent Biosolutions Inc   58.56 %$ 137.200  Millions$ 234.300  Millions
Elanco Animal Health Incorporated  58.33 %$ 798.000  Millions$ 1,368.000  Millions
Siga Technologies Inc  57.17 %$ 23.441  Millions$ 41.002  Millions
Schrodinger Inc   55.07 %$ 32.432  Millions$ 58.889  Millions
Zai Lab Limited  54.70 %$ 58.149  Millions$ 106.311  Millions
Mallinckrodt Plc  54.52 %$ 282.000  Millions$ 517.200  Millions
International Stem Cell Corporation  54.50 %$ 1.458  Millions$ 2.675  Millions
Organon and Co   54.36 %$ 847.000  Millions$ 1,558.000  Millions
Teva Pharmaceutical Industries Limited  51.98 %$ 2,153.000  Millions$ 4,142.000  Millions
Prestige Consumer Healthcare Inc   51.25 %$ 136.188  Millions$ 265.710  Millions
Amphastar Pharmaceuticals Inc   50.83 %$ 93.470  Millions$ 183.903  Millions
Bullfrog Ai Holdings Inc   49.63 %$ 0.107  Millions$ 0.215  Millions
Opko Health Inc   48.92 %$ 80.017  Millions$ 163.580  Millions
Cv Sciences Inc   48.58 %$ 1.450  Millions$ 2.985  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.